COVID‐19 disease frequency, risk factors, and re‐infection rates in patients with autoimmune rheumatic disease receiving rituximab

Rituximab, which is used in autoimmune rheumatic diseases (ARD), can cause both an increased risk of development of COVID‐19 disease and re‐infection due to its potent and long‐acting immunosuppression. So, we aimed to evaluate the frequency, risk factors and re‐infection rates of COVID‐19 in ARD patients receiving rituximab.

[1]  M. Gianfrancesco,et al.  SARS-CoV-2 breakthrough infections among vaccinated individuals with rheumatic disease: results from the COVID-19 Global Rheumatology Alliance provider registry , 2022, RMD Open.

[2]  Shengqian Xu,et al.  Prevalence and risk of COVID-19 in patients with rheumatic diseases: a systematic review and meta-analysis , 2022, Clinical Rheumatology.

[3]  R. Yeung,et al.  Evaluation of Serious Infection in Pediatric Patients with Low Immunoglobulin Levels Receiving Rituximab for Granulomatosis with Polyangiitis or Microscopic Polyangiitis , 2022, Rheumatology and Therapy.

[4]  L. Krupp,et al.  Risk of COVID-19 infection and severe disease in MS patients on different disease-modifying therapies , 2022, Multiple Sclerosis and Related Disorders.

[5]  L. Calabrese,et al.  Breakthrough SARS‐CoV‐2 infections in immune mediated disease patients undergoing B cell depleting therapy: A retrospective cohort analysis , 2022, medRxiv.

[6]  M. Patyk,et al.  Recurrent COVID-19 Polymerase Chain Reaction (PCR) Positivity in 2 Patients During the Current Health Care System Crisis , 2022, The American journal of case reports.

[7]  D. Courvoisier,et al.  Incidence of COVID-19 in patients treated with infliximab compared with patients treated with rituximab , 2021, RMD Open.

[8]  J. Stellmann,et al.  Hypogammaglobulinemia and Infections in Patients With Multiple Sclerosis Treated With Rituximab , 2021, Neurology: Neuroimmunology & Neuroinflammation.

[9]  S. Hejazi,et al.  Recurrence of COVID-19 in a Patient With NMO Spectrum Disorder While Treating With Rituximab , 2021, The neurologist.

[10]  M. Dalamaga,et al.  Real world evidence: Patients with refractory pemphigus treated with Rituximab , 2021, Metabolism open.

[11]  L. Trupin,et al.  Association Between Tumor Necrosis Factor Inhibitors and the Risk of Hospitalization or Death Among Patients With Immune-Mediated Inflammatory Disease and COVID-19 , 2021, JAMA network open.

[12]  Thamil Vaani Komarasamy,et al.  Hyperinflammatory Immune Response and COVID-19: A Double Edged Sword , 2021, Frontiers in Immunology.

[13]  F. Paliogianni,et al.  Protracted severe COVID-19 pneumonia following rituximab treatment: caution needed , 2021, Rheumatology International.

[14]  M. López-Dosil,et al.  Incidence, clinical presentation, relapses and outcome of SARS-CoV-2 infection in patients treated with anti-CD20 monoclonal antibodies. , 2021, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[15]  K. Winthrop,et al.  Long-Term Safety of Rituximab (Risks of Viral and Opportunistic Infections) , 2021, Current Rheumatology Reports.

[16]  A. Langer-Gould,et al.  Multiple sclerosis, rituximab, and COVID‐19 , 2021, Annals of clinical and translational neurology.

[17]  Julie M. Woessner,et al.  COVID-19 outcomes in patients with inflammatory rheumatic and musculoskeletal diseases treated with rituximab: a cohort study , 2021, The Lancet Rheumatology.

[18]  K. Winthrop,et al.  Second COVID-19 infection in a patient with granulomatosis with polyangiitis on rituximab , 2021, Annals of the Rheumatic Diseases.

[19]  L. Trupin,et al.  Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry , 2021, Annals of the Rheumatic Diseases.

[20]  Gaurav D. Gaiha,et al.  Persistence and Evolution of SARS-CoV-2 in an Immunocompromised Host , 2020, The New England journal of medicine.

[21]  C. Wobus,et al.  Prolonged Severe Acute Respiratory Syndrome Coronavirus 2 Replication in an Immunocompromised Patient , 2020, The Journal of infectious diseases.

[22]  E. De Robertis,et al.  Is recurrence possible in coronavirus disease 2019 (COVID-19)? Case series and systematic review of literature , 2020, European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology.

[23]  A. Boteanu,et al.  High rates of severe disease and death due to SARS-CoV-2 infection in rheumatic disease patients treated with rituximab: a descriptive study , 2020, Rheumatology International.

[24]  D. Isenberg,et al.  B-cell depletion with rituximab in the COVID-19 pandemic: where do we stand? , 2020, The Lancet Rheumatology.

[25]  A. Bar-Or,et al.  Neurological immunotherapy in the era of COVID-19 — looking for consensus in the literature , 2020, Nature Reviews Neurology.

[26]  E. García-Lorenzo,et al.  Clinical course, severity and mortality in a cohort of patients with COVID-19 with rheumatic diseases , 2020, Annals of the Rheumatic Diseases.

[27]  M. Ebert,et al.  Long, relapsing, and atypical symptomatic course of COVID-19 in a B-cell-depleted patient after rituximab , 2020, Seminars in Arthritis and Rheumatism.

[28]  C. Nabhan,et al.  Rituximab biosimilars in hematologic malignancies: the need for a real-world approach. , 2020, Future oncology.

[29]  Aaron J. Wilk,et al.  A single-cell atlas of the peripheral immune response in patients with severe COVID-19 , 2020, Nature Medicine.

[30]  A. Skapenko,et al.  Increased risk for severe COVID-19 in patients with inflammatory rheumatic diseases treated with rituximab , 2020, Annals of the Rheumatic Diseases.

[31]  L. Lopalco,et al.  Humoral Immune Responses in COVID-19 Patients: A Window on the State of the Art , 2020, Frontiers in Immunology.

[32]  Xuetao Cao.  COVID-19: immunopathology and its implications for therapy , 2020, Nature Reviews Immunology.

[33]  Bo Diao,et al.  Reduction and Functional Exhaustion of T Cells in Patients With Coronavirus Disease 2019 (COVID-19) , 2020, Frontiers in Immunology.

[34]  P. Emery,et al.  Predicting Severe Infection and Effects of Hypogammaglobulinemia During Therapy With Rituximab in Rheumatic and Musculoskeletal Diseases , 2019, Arthritis & rheumatology.

[35]  O. Boyman,et al.  Systematic Review of Safety and Efficacy of Rituximab in Treating Immune-Mediated Disorders , 2019, Front. Immunol..

[36]  A. Akdoğan,et al.  Starting of biological disease modifying antirheumatic drugs may be postponed in rheumatoid arthritis patients with multimorbidity , 2018, Medicine.

[37]  G. Giardino,et al.  Risk factors predisposing to the development of hypogammaglobulinemia and infections post-Rituximab , 2017, International reviews of immunology.